Nexam Chemical carries out a rights issue of units of approximately SEK 62m and postpones publication of the interim report of the first quarter 2020
02/14/2020
The board of directors of Nexam Chemical Holding AB, Reg. No. 556919-9432 (”Nexam Chemical” or the “Company”), has today, on February 14, 2020, subject to approval by the extraordinary general meeting, resolved to carry out a rights issue of a maximum of 2,813,292 units, each unit containing four (4) shares, one (1) warrant series TO1 and one (1) warrant series TO2 (the ”Rights Issue”). At full subscription in the Rights Issue, Nexam Chemical will receive gross proceeds of approximately SEK 62m before issue costs, and upon full exercise of all warrants, Nexam Chemical will receive additional proceeds of SEK 42m before issue costs. Nexam Chemical has received subscription commitments and subscription intentions of approximately SEK 12.8m, corresponding to approximately 20.7 percent of the Rights Issue. The Rights Issue is subject to approval by the extraordinary general meeting on March 4, 2020. Notice of the extraordinary general meeting will be published through a separate press release. Due to the Rights Issue, the board of directors has resolved to postpone the publication of the interim report for the first quarter of 2020 to May 8, 2020.
Background and reason in short
In 2019, Nexam Chemical showed a sales growth of almost 20 percent, driven by a positive development within Performance Chemicals, where the Company has a strong position in several product segments and a good underlying growth. Clearest is Nexam Chemical’s position in PET foam where volumes are increasing rapidly, driven by the wind power industry, which is shifting to PET foam as manufacturing material in the blades. The Company also believes that the growth potential is significant in the high performance product segment and polyethylene pipes segment.
To meet the growing demand in Performance Chemicals, Nexam Chemical needs to invest in increased production capacity. Furthermore, increasing volumes drive increased working capital tied up, which means that the Company needs to strengthen its financial position. A strong financial position is also important for Nexam Chemical to be viewed at as a long-term and stable supplier, which is often crucial in major procurements.
Overall, Nexam Chemical believes that the capital from the Rights Issue will strengthen the long-term growth potential of the Company. If the Company develops according to plan, there are prerequisites for additional capital to be raised through the warrants issued in the Rights Issue. Nexam Chemical estimates that Performance Chemicals can grow substantially in the coming years and that there may therefore be additional investment needs, which can potentially be met through additional capital through the exercise of warrants.
In order to enable the growth initiatives planned by the Company, the board of directors of Nexam Chemical has resolved on the upcoming Rights Issue, which, at full subscription, will provide the Company with approximately SEK 62m before issue costs, excluding exercise of warrants. Issue costs are estimated to amount to approximately SEK 3m and consists mainly of compensation to financial and legal advisors. The net proceeds of approximately SEK 59m are considered to be sufficient to meet the Company’s working capital needs for at least the coming twelve-month period.
The net proceeds of approximately SEK 59m is intended to be used for the following areas, stated in priority order:
-
Investments in production capacity (approximately SEK 20m)
Research and development of new products (approximately SEK 25m)
Strengthening working capital (approximately SEK 11m)
Strengthening the sales organization (approximately SEK 3m)
In case the warrants are exercised for subscription of shares, the Company will receive additional proceeds of approximately SEK 42m before issue costs, which are estimated to approximately SEK 1m. The additional net proceeds of approximately SEK 41m are intended to be used for the following areas, stated in priority order:
-
Investments in production capacity (approximately SEK 10m)
Research and development of new products (approximately SEK 8m)
Expansion in new segments/markets (approximately SEK 13m)
Strengthening working capital (approximately SEK 5m)
Strengthening the organization (approximately SEK 5m)
Preliminary time plan for the Rights Issue
March 4, 2020 Extraordinary general meeting
March 9, 2020 Last day of trading including the right to receive unit rights
March 10, 2020 First day of trading excluding the right to receive unit rights
March 11, 2020 Record date for participation in the Rights Issue
March 16 – 26, 2020 Trading in unit rights
March 16 – 30, 2020 Subscription period
Around April 3, 2020 Publication of the outcome of the Rights Issue
Terms and conditions of the Rights Issue
The board of directors of Nexam Chemical has today, on February 14, 2020, subject to approval by the extraordinary general meeting, resolved to carry out a Rights Issue of a maximum of 2,813,292 units. For each (1) share in the Company held on the record date on March 11, 2020, one (1) unit right is obtained. Twenty-four (24) unit rights entitle to subscription of one (1) unit, containing four (4) shares, one (1) warrant series TO1 and one (1) warrant series TO2. The subscription price amounts to SEK 22, corresponding to a subscription price of SEK 5.50 per share. At full subscription in the Rights Issue, Nexam Chemical will receive gross proceeds of approximately SEK 62m before issue costs, excluding the additional capital contribution that may come from exercise of warrants. The warrants are issued free of charge. Subscription of units with or without unit rights takes place during the period March 16 – 30, 2020. Unit rights not exercised during the subscription period will become invalid and lose their value. Trading in unit rights will take place on Nasdaq First North Premier Growth Market during the period March 16 – 26, 2020.
If not all units are subscribed for by exercise of unit rights, allotment of the remaining units shall be made within the highest amount of the Rights Issue: firstly, to those who have subscribed for units by exercise of unit rights (regardless of whether they were shareholders on the record date or not) and who have applied for subscription of units without exercise of unit rights and if allotment to these cannot be made in full, allotment shall be made pro rata in relation to the number of unit rights that each and every one of those, who have applied for subscription of units without exercise of unit rights, have exercised for subscription of units; and secondly, to those who have applied for subscription of units in the Rights Issue without exercise of unit rights and if allotment to these cannot be made in full, allotment shall be made pro rata in relation to the number of units the subscriber in total has applied for subscription of units. To the extent that allotment in any section above cannot be done pro rata, allotment shall be determined by drawing of lots.
Each warrant series TO1 entitles the right to subscribe for one (1) new share in the Company at a subscription price of SEK 6.50 during the period September 6 – 17, 2021. This means that the additional capital contribution from the warrants of series TO1 may amount to a maximum of approximately SEK 18m. Each warrant of series TO2 entitles the right to subscribe for one (1) new share in the Company at a subscription price of SEK 8.50 during the period September 5 – 16, 2022. This means that the additional capital contribution from the warrants of series TO2 may amount to a maximum of approximately SEK 24m.
Full terms and conditions for the Rights Issue and other information about the Company will be stated in the EU Growth Prospectus which will be published no later than the day before the start of the subscription period.
Subscription commitments and subscription intentions
In connection with the Rights Issue, a number of existing shareholders, including the CEO, CFO and all members of the board of directors, have undertaken to subscribe or declared their intention to subscribe their respective pro rata shares in the Rights Issue for a total of SEK 12.8m, corresponding to approximately 20.7 percent of the Rights Issue. No commission is paid for the subscription commitments.
Change of share capital and number of shares and dilution
At full subscription in the Rights Issue the number of shares in the Company will increase from 67,519,019 to 78,772,187 and the share capital will increase from SEK 1,298,442.673109 to SEK 1,514,849.750038, corresponding to a dilution effect of approximately 14.3 percent. At full exercise of all warrants in the Rights Issue the number of shares in the Company will increase with an additional 5,626,584 shares and the share capital with an additional SEK 108,203.538466, to 84,398,771 shares respective SEK 1,623,053.288504, corresponding to a dilution effect of approximately 6,7 percent. The total dilution at full subscription in the Rights Issue and full exercise of all warrants thus amounts to a maximum of approximately 20 percent.
Extraordinary general meeting
The board of directors’ resolution on the Rights Issue is subject to approval by the extraordinary general meeting on March 4, 2020. Notice of the extraordinary general meeting will be published through a separate press release.
Postponement of publication of the interim report for the first quarter of 2020
Due to the Rights Issue, the board of directors of Nexam Chemical has resolved that the interim report for the first quarter of 2020 will be published on May 8, 2020 instead of April 28, 2020, as previously planned.
Advisors
Financial advisor to Nexam Chemical in connection with the Rights Issue is Erik Penser Bank AB and Setterwalls Advokatbyrå AB is legal advisor to Nexam Chemical in connection with the Rights Issue.